Company intelligence / Profile preview

March Biosciences

Houston, Texas, United Statesmarch.bio ↗

Ownership: Private
Development stage: Phase 1

Overview

MB-105 has demonstrated a favorable safety profile and durable remissions in relapsed T-cell lymphoma patients in a Phase 1 clinical trial at Baylor College of Medicine. The company has now dosed the first patient in its Phase 2 clinical trial for MB-105 in April 2025, with the trial being conducted at multiple centers including The University of Texas MD Anderson Cancer Center.

Therapeutic areas: Oncology
Modalities: CAR-T cell therapy
Industry: Biotech

Drug pipeline

6 assets

MB-105

5 more assets in the full pipeline.

Request access →

Partnerships

Volnay Therapeutics

Beyond the preview

Go deeper on March Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on March Biosciences.

Explore the full profile